Adaptimmune Therapeutics plc American Depositary Shares(ADAP)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $0.04 – $0.36
- YTD
- +0.00%
- IV Rank (30D)
- 0.01
- Straddle Price
- $1.50
- P/C Vol Ratio
- 1.00
- Market Cap
- $0.0B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.00% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 8.75% (VRP-adj) |
| WACC | 7.77% |
| Volatility Risk Premium | -417.9pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $-0.2B |
| Book / Price | -79.4% |
| Gross Margin (TTM) | 94.7% |
| FCF Margin (TTM) | -299.7% |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $0.10 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.08 |
| Bollinger Width / SMA20 | 285948.9% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | n/a | 0% | |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $0.10 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) (2836)
- Exchange
- XNAS
- Market Cap
- $0.0B
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +0.40% | 5 |
| Feb | +8.22% | 5 |
| Mar | -16.83% | 6 |
| Apr | -1.20% | 5 |
| May | -8.10% | 5 |
| Jun | -8.35% | 5 |
| Jul | -11.01% | 5 |
| Aug | +7.33% | 5 |
| Sep | +12.56% | 5 |
| Oct | -16.27% | 5 |
| Nov | +3.73% | 4 |
| Dec | +4.35% | 4 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-12 | After-Close | 15.91% | 5.45% | 0.34x | Within |
| 2024-11-13 | Pre-Market | 350.44% | 3.55% | 0.01x | Within |
| 2025-03-20 | Pre-Market | 166.67% | 37.76% | 0.23x | Within |
| 2025-05-13 | Pre-Market | 922.79% | 11.63% | 0.01x | Within |
| 2025-08-13 | Pre-Market | 1199.74% | 1.81% | 0.00x | Within |
- IV Rank (30D)
- 0.01
- IV Rank (7D)
- 0.01
- Avg IV
- 0.1%
- Straddle (30D)
- $1.50
- Straddle (7D)
- $1.50
- P/C Volume
- 1.00
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.47
- Correlation (SPY)
- 1.8%
- R²
- 0.00
- Ann. Volatility
- 282.8%
- SPY Volatility
- 10.9%
Low volatility - stock moves less than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2025-09-03 | Gavin Wood | Chief Financial Officer | Sell (S) | −96,000 | $0.01 | -$950 | EDGAR |
| 2025-08-29 | William C JR Bertrand | Chief Operating Officer | Sell (S) | −207,000 | $0.01 | -$2.1K | EDGAR |
| 2025-08-19 | Ali Behbahani | Director | Sell (S) | −19,500,000 | $0.01 | -$229.2K | EDGAR |
| 2025-07-30 | EcoR1 Capital, LLC | 10%+ Owner | Sell (S) | −64,052,538 | $0.11 | -$6.89M | EDGAR |
| 2025-02-20 | Joanna Elizabeth Brewer | Chief Scientific Officer | Grant (A) | +2,686,728 opt | — | EDGAR | |
| 2025-02-20 | Adrian Rawcliffe | Chief Executive Officer | Grant (A) | +8,572,080 opt | — | EDGAR | |
| 2025-02-20 | Elliot Norry | Chief Medical Officer | Grant (A) | +2,686,728 opt | — | EDGAR | |
| 2025-02-20 | Cintia Piccina | Chief Commercial Officer | Grant (A) | +2,686,728 opt | — | EDGAR | |
| 2025-02-20 | John Lunger | Chief Patient Supply Officer | Grant (A) | +2,686,728 opt | — | EDGAR | |
| 2025-02-20 | William C JR Bertrand | Chief Operating Officer | Grant (A) | +2,686,728 opt | — | EDGAR | |
| 2025-01-17 | William C JR Bertrand | Chief Operating Officer | Sell (S) | −5,584 | $0.58 | -$3.2K | EDGAR |
| 2025-01-17 | John Lunger | Chief Patient Supply Officer | Sell (S) | −5,584 | $0.58 | -$3.2K | EDGAR |
| 2025-01-17 | Elliot Norry | Chief Medical Officer | Sell (S) | −5,584 | $0.58 | -$3.2K | EDGAR |
| 2025-01-17 | Adrian Rawcliffe | Chief Executive Officer | Sell (S) | −30,601 | $0.58 | -$17.8K | EDGAR |
| 2025-01-15 | William C JR Bertrand | Chief Operating Officer | Sell (S) | −19,542 | $0.58 | -$11.4K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 10%+ Owner | 127,805,220 | $7.40M | -$6.89M | 1 | 2025-07-30 |
| 2 | FOREST BASKETT | 10%+ Owner | 82,978,668 | $4.80M | $5.00M | 1 | 2020-01-28 |
| 3 | Peter W. Sonsini | 10%+ Owner | 82,978,668 | $4.80M | $5.00M | 1 | 2020-01-28 |
| 4 | DAVID M MOTT | Director | 19,500,000 | $1.13M | $5.00M | 6 | 2024-07-01 |
| 5 | SCOTT D SANDELL | 10%+ Owner | 19,500,000 | $1.13M | $5.00M | 1 | 2020-01-28 |
| 6 | Anthony A. Jr. Florence | 10%+ Owner | 19,500,000 | $1.13M | $5.00M | 1 | 2020-01-28 |
| 7 | Ali Behbahani | Director | 14,671,794 | $849.5K | $4.77M | 8 | 2025-08-19 |
| 8 | HELEN KATRINA TAYTON-MARTIN | Chief Business & Strgy Officer | 1,800,000 | $104.2K | -$2.20M | 9 | 2024-01-17 |
| 9 | William C JR Bertrand | Chief Operating Officer | 986,352 | $57.1K | -$44.0K | 23 | 2025-08-29 |
| 10 | Garry E Menzel | Director | 275,703 | $16.0K | -$43.4K | 5 | 2024-07-01 |
| 11 | Lawrence M Alleva | Director | 130,764 | $7.6K | $34.3K | 7 | 2024-07-01 |
| 12 | Adrian Rawcliffe | Chief Executive Officer | 44,327 | $2.6K | -$518.7K | 30 | 2025-02-20 |
| 13 | Cintia Piccina | Chief Commercial Officer | 18,421 | $1.1K | -$89.8K | 8 | 2025-02-20 |
| 14 | John Lunger | Chief Patient Supply Officer | 7,510 | $435 | -$218.0K | 27 | 2025-02-20 |
| 15 | Elliot Norry | Chief Medical Officer | 7,510 | $435 | -$118.2K | 20 | 2025-02-20 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| TTM Revenue | $0.1B |
| TTM Net Income | $-0.2B |
| TTM EPS | $-0.11 |